BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong revenue growth, improved losses, and a solid cash position. The Fast Track designation for BRTX-100 and IND clearance for cervical disc pain are positive catalysts. Concerns remain around regulatory risks and lack of clear guidance on trials. However, the strategic focus on expanding clinical programs and potential licensing agreements are promising. The absence of a share repurchase program is a minor negative, but overall sentiment is positive due to strong financial performance and strategic advancements.
Key Financial Performance
Revenue $401,000, a 175% increase year-over-year.
Loss from Operations $11.6 million, a 24% improvement from a loss of $15.2 million in 2023.
Net Loss $9 million, or $1.16 per share, a 14% improvement from a net loss of $10.4 million, or $2.47 per share, in 2023.
Cash Used in Operating Activities $8.2 million.
Cash, Cash Equivalents and Marketable Securities $10.7 million, with no outstanding debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRTX-100: A novel cell-based therapeutic targeting chronic lumbar disc disease, currently in Phase 2 trial with positive preliminary data.
ThermoStem: Developing cell-based therapy for obesity and metabolic disorders using brown adipose-derived stem cells.
FDA Fast Track designation: BRTX-100 received Fast Track designation, facilitating development and review process.
IND clearance for cervical trial: FDA cleared IND for Phase 2 trial of BRTX-100 targeting chronic cervical discogenic pain.
Financial results: Revenue grew 175% year-over-year to $401,000; loss from operations improved by 24%.
Cash position: Ended 2024 with cash, cash equivalents, and marketable securities of $10.7 million.
Intellectual Property: Expanded ThermoStem patent portfolio to ensure long-term market exclusivity.
Commercial discussions: Ongoing discussions with a regenerative medicine company for potential licensing agreements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces uncertainties related to regulatory approvals, particularly with the FDA's Fast Track designation and IND clearance for clinical trials. Any changes in regulatory requirements could impact timelines and costs.
Financial Risks: Despite a significant revenue growth of 175% year-over-year, the company reported a net loss of $9 million. Continued losses may affect financial stability and investor confidence.
Operational Risks: The ongoing Phase 2 clinical trials for BRTX-100 and ThermoStem carry inherent risks, including the potential for adverse events or failure to meet primary and secondary endpoints, which could delay product development.
Competitive Pressures: The company operates in a competitive landscape for regenerative medicine and metabolic therapies, where advancements by competitors could impact market share and pricing strategies.
Supply Chain Challenges: The development of cell-based therapies may face supply chain issues, particularly in sourcing materials for clinical trials, which could affect timelines and costs.
Economic Factors: Broader economic conditions, including funding availability and market demand for regenerative therapies, could influence the company's growth and operational strategies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BRTX-100 Clinical Program: The Phase 2 trial for BRTX-100 is progressing well, with preliminary data showing positive trends. The FDA granted Fast Track designation for this program, facilitating closer collaboration with the FDA.
ThermoStem Program: The company is developing ThermoStem, targeting obesity and metabolic disorders, and is expanding its intellectual property portfolio to ensure market exclusivity.
Cervical Disc Pain IND: The FDA cleared the IND application for a Phase 2 trial for BRTX-100 targeting chronic cervical discogenic pain, allowing the company to bypass preclinical studies.
2024 Revenue Growth: BioRestorative's revenue grew 175% year-over-year to $401,000 for 2024.
Net Loss Improvement: The net loss for 2024 was $9 million, a 14% improvement from the previous year.
Financial Position: The company ended 2024 with cash, cash equivalents, and marketable securities of $10.7 million and no outstanding debt.
Future Financial Flexibility: The company aims to become less dependent on capital markets as it continues to improve financial performance and execute strategic goals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the resolution of annular tears and decreased protrusion size something that happens spontaneously?
A:No, it’s not something that happens spontaneously, especially with annular tears. Bulging may happen in early degeneration, but with degenerative disease, the disc is degenerating.
Q:Do you view the cervical program as a one-off expansion or part of a broader strategy?
A:The goal is a broader strategy. The cervical space was strategically chosen because if it works for lumbar, it should work for cervical.
Q:Is there an intent to design the cervical study as a registration enabling study similar to lumbar disc disease?
A:Yes, absolutely. We plan to leverage our lumbar data for faster regulatory approvals.
Q:What is the enrollment update for the Lumbar trial and estimation for completing the first 100 patients?
A:Enrollment is going well, but we haven't given out numbers yet as we want to explore regulatory opportunities first.
Q:What should we expect for Cartessa revenues going forward?
A:Expect more consistency in revenues, but it’s still early in the commercial relationship.
Q:Review of Unclear Management Responses
A:Management did not provide specific enrollment numbers for the Lumbar trial, stating they want to meet with the FDA first for clarity. Additionally, while they mentioned Cartessa revenues would be more consistent, they avoided giving a definitive forecast.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accelerated Biologics
Analog Scale
Annual Meeting
Application Approval
Approval BLA
BAT exosomes
BLA approval
Benefits program
BioRestorative FDA
Biologics License
CLDD study
Development Conference
Disability Index
FDA IND
FDA program
GLP
adipose stem
agreement
animal study
cell product
designation
disease program
improvement loss
loss share
metabolic disorder
milestone
obesity metabolic
patent
platform
program FDA
stage
study Phase
weight loss
BRTX Transcript
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals significant financial challenges, including a drastic revenue decline and increased losses. The heavy dependence on clinical trials, regulatory risks, and cash burn further exacerbate concerns. Additionally, management's lack of clarity on revenue guidance and FDA timelines adds uncertainty. Despite the large market potential for BioCosmeceuticals, the absence of clear revenue projections and reliance on partnerships indicate strategic vulnerabilities. The overall sentiment from the call and Q&A is negative, suggesting a strong negative stock price reaction over the next two weeks.
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses
Unknown5-14
The earnings call reveals several concerns: a significant revenue decline, increased net loss, and operational losses, along with uncertainties in clinical trials and market competition. Despite a strong cash position, these issues overshadow positive aspects like the FDA's Fast Track designation and potential patient recruitment improvements. The Q&A section highlights management's unclear responses, particularly regarding interim analysis, adding to investor uncertainty. Given these factors, the stock is likely to experience a negative reaction, reflecting investor concerns over financial performance and strategic execution.
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals several concerning factors: a significant increase in net loss, decreased revenue, and a rise in operational costs. Despite positive deferred revenue and no debt, financial instability is evident. The Q&A section highlights uncertainties, particularly regarding clinical trials and regulatory risks. No share repurchase program is announced, and market competition remains a threat. These factors, combined with the absence of strong positive catalysts, suggest a likely negative stock price movement over the next two weeks.
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call summary shows strong revenue growth and improved financial metrics, but the company still faces significant risks, including regulatory uncertainties and financial losses. The Q&A session highlighted management's cautious responses regarding trial enrollment and cash burn, suggesting potential uncertainties. The lack of a shareholder return plan and the competitive landscape further contribute to a neutral sentiment. Despite positive developments like FDA Fast Track designation, the absence of immediate catalysts and ongoing challenges balance the overall outlook.
BRTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
